Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri(Brigham and Women's Hospital), Douglas R. Adkins(Washington University in St. Louis), Evisa Gjini(Brigham and Women's Hospital), Jessica Ley(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Vickie Y. Jo(Brigham and Women's Hospital), Rebecca D. Chernock(Washington University in St. Louis), Rachel Riley(Rowan University), Erica K. Barnell(Washington University in St. Louis), Youstina Hanna(Princess Margaret Cancer Centre), Ann Marie Egloff(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Dorina Kallogjeri(Washington University in St. Louis), Jay F. Piccirillo(Washington University in St. Louis), Malachi Griffith(Washington University in St. Louis), Glenn J. Hanna(Dana-Farber Cancer Institute), Patrik Pipkorn(Washington University in St. Louis), Jason Kass(Brigham and Women's Hospital), Tenny Mudianto(New York University), Randal C. Paniello(Washington University in St. Louis), Zachary L. Skidmore(James S. McDonnell Foundation), Iulia Cirlan(Princess Margaret Cancer Centre), Ana Lako(Brigham and Women's Hospital), Katie M. Campbell(University of California, Los Angeles), Brian Nussenbaum(Washington University in St. Louis), Tianxiang Lin(Wenzhou Medical University), Nicholas C. Spies(James S. McDonnell Foundation), Scott J. Rodig(Brigham and Women's Hospital), David T. Mulder(Princess Margaret Cancer Centre), Mackenzie Daly(University of Colorado Colorado Springs), Trevor J. Pugh(Boston Children's Hospital), Wade L. Thorstad(Washington University in St. Louis), Gavin P. Dunn(Brigham Young University), Robert I. Haddad(Georgetown University), Hiram A. Gay(Washington University in St. Louis), Paul Zolkind(Washington University in St. Louis), Matthew D. Stachler(University of California, San Francisco), Tiantian Li(Princess Margaret Cancer Centre), Peter Oppelt(Washington University in St. Louis), Liye Zhou(Dana-Farber Cancer Institute), Obi L. Griffith(Washington University in St. Louis), Loren S. Michel(Memorial Sloan Kettering Cancer Center), Ian S. Hagemann(Washington University in St. Louis)
Cited by 368
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k